Literature DB >> 23744073

Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase.

Saurabh Khasnavis1, Anamitra Ghosh1, Avik Roy1, Kalipada Pahan2.   

Abstract

Although Parkinson disease (PD) is a progressive neurodegenerative disorder, available animal models do not exhibit irreversible neurodegeneration, and this is a major obstacle in finding out an effective drug against this disease. Here we delineate a new irreversible model to study PD pathogenesis. The model is based on simple castration of young male mice. Levels of inducible nitric-oxide synthase (iNOS), glial markers (glial fibrillary acidic protein and CD11b), and α-synuclein were higher in nigra of castrated male mice than normal male mice. On the other hand, after castration, the level of glial-derived neurotrophic factor (GDNF) markedly decreased in the nigra of male mice. Accordingly, castration also induced the loss of tyrosine hydroxylase-positive neurons in the nigra and decrease in tyrosine hydroxylase-positive fibers and neurotransmitters in the striatum. Reversal of nigrostriatal pathologies in castrated male mice by subcutaneous implantation of 5α-dihydrotestosterone pellets validates an important role of male sex hormone in castration-induced nigrostriatal pathology. Interestingly, castration was unable to cause glial activation, decrease nigral GDNF, augment the death of nigral dopaminergic neurons, induce the loss of striatal fibers, and impair neurotransmitters in iNOS(-/-) male mice. Furthermore, we demonstrate that iNOS-derived NO is responsible for decreased expression of GDNF in activated astrocytes. Together, our results suggest that castration induces nigrostriatal pathologies via iNOS-mediated decrease in GDNF. These results are important because castrated young male mice may be used as a simple, toxin-free, and nontransgenic animal model to study PD-related nigrostriatal pathologies, paving the way for easy drug screening against PD.

Entities:  

Keywords:  Castration; Microglia; Neurodegeneration; Neuroinflammation; Nitric-oxide Synthase; Parkinson Disease

Mesh:

Substances:

Year:  2013        PMID: 23744073      PMCID: PMC3774356          DOI: 10.1074/jbc.M112.443556

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease.

Authors:  Michael S Okun; Benjamin L Walter; William M McDonald; Joyce L Tenover; Joanne Green; Jorge L Juncos; Mahlon R DeLong
Journal:  Arch Neurol       Date:  2002-11

2.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism.

Authors:  K T Akama; C Albanese; R G Pestell; L J Van Eldik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

5.  Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.

Authors:  Gunnar P H Dietz; Paoloa C Valbuena; Birgit Dietz; Katrin Meuer; Patrick Müeller; Jachen H Weishaupt; Mathias Bähr
Journal:  Brain Res       Date:  2006-04-12       Impact factor: 3.252

6.  Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia.

Authors:  Xiaojuan Liu; Malabendu Jana; Subhajit Dasgupta; Sreenivas Koka; Jun He; Charles Wood; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

7.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

8.  DNA deaminating ability and genotoxicity of nitric oxide and its progenitors.

Authors:  D A Wink; K S Kasprzak; C M Maragos; R K Elespuru; M Misra; T M Dunams; T A Cebula; W H Koch; A W Andrews; J S Allen
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

9.  A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty.

Authors:  Max J Kurz; Konstantinos Pothakos; Sakeena Jamaluddin; Melissa Scott-Pandorf; Chris Arellano; Yuen-Sum Lau
Journal:  Neurosci Lett       Date:  2007-10-05       Impact factor: 3.046

10.  Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.

Authors:  S Hunot; F Boissière; B Faucheux; B Brugg; A Mouatt-Prigent; Y Agid; E C Hirsch
Journal:  Neuroscience       Date:  1996-05       Impact factor: 3.590

View more
  14 in total

1.  Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.

Authors:  James W S Young; Rinku Sutradhar; Jagadish Rangrej; Connie Marras; Neil Fleshner; Shabbir M H Alibhai
Journal:  World J Urol       Date:  2017-02-15       Impact factor: 4.226

Review 2.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

3.  Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism.

Authors:  Jing Gong; Éva M Szego; Andrei Leonov; Eva Benito; Stefan Becker; Andre Fischer; Markus Zweckstetter; Tiago Outeiro; Anja Schneider
Journal:  J Neurosci       Date:  2019-02-22       Impact factor: 6.167

4.  Chronic depletion of gonadal testosterone leads to blood-brain barrier dysfunction and inflammation in male mice.

Authors:  Afnan Atallah; Sakina Mhaouty-Kodja; Valérie Grange-Messent
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 5.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

6.  Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.

Authors:  Sathiya Sekar; Sugumar Mani; Barathidasan Rajamani; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Abid Bhat; Bipul Ray; Musthafa Mohamed Essa; Gilles J Guillemin; Saravana Babu Chidambaram
Journal:  Neurotox Res       Date:  2018-07-13       Impact factor: 3.911

7.  Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.

Authors:  Danielle E Mor; Elpida Tsika; Joseph R Mazzulli; Neal S Gould; Hanna Kim; Malcolm J Daniels; Shachee Doshi; Preetika Gupta; Jennifer L Grossman; Victor X Tan; Robert G Kalb; Kim A Caldwell; Guy A Caldwell; John H Wolfe; Harry Ischiropoulos
Journal:  Nat Neurosci       Date:  2017-09-18       Impact factor: 24.884

8.  Nervonic acid amends motor disorder in a mouse model of Parkinson's disease.

Authors:  Dandong Hu; Yujuan Cui; Ji Zhang
Journal:  Transl Neurosci       Date:  2021-05-25       Impact factor: 1.757

9.  Testosterone Protects Mitochondrial Function and Regulates Neuroglobin Expression in Astrocytic Cells Exposed to Glucose Deprivation.

Authors:  Nicolas Toro-Urrego; Luis M Garcia-Segura; Valentina Echeverria; George E Barreto
Journal:  Front Aging Neurosci       Date:  2016-06-27       Impact factor: 5.750

10.  Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features.

Authors:  Jesús de Pedro-Cuesta; Pablo Martínez-Martín; Alberto Rábano; María Ruiz-Tovar; Enrique Alcalde-Cabero; Miguel Calero
Journal:  Front Aging Neurosci       Date:  2016-06-13       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.